T cell company Kiadis to acquire NK cell company Cytosen

In a deal that merges cell therapy technologies to improve outcomes of stem cell transplant patients, T cell company Kiadis will acquire NK cell company Cytosen in a deal valued at EUR19.4 million ($21.9 million)

Additionally, Kiadis Pharma N.V. (Euronext:KDS) will add CAR T cell pioneer Carl June to its advisory board. June is a scientific adviser to CytoSen Therapeutics Inc. (Orlando, Fla.)...